Biogen | BIIB - Debt



Biogen reported $6.59B in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
ALKERMES USD 72.68M 72.68M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
Bayer EUR 39.39B 1.31B Mar/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Merck USD 34.84B 2.27B Mar/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Novartis USD 31.27B 12M Mar/2025
Pfizer USD 60.93B 1.18B Jun/2025
PTC Therapeutics USD 286.01M 2.12B Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Sanofi 22.28B 1.24B Jun/2025
Sanofi 22.28B 4.38B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Teva Pharmaceutical Industries USD 17.52B 872M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
United Therapeutics USD 200M 100M Mar/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025